# VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA

> **NCT05135455** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 467 (actual)

## Conditions studied

- Prevention of Infectious Disease Caused by SARS-CoV-2

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05135455
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-21
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 467 (ACTUAL)
- **Last updated:** 2024-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05135455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05135455, "VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05135455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*